Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
A Prospective Observational Post-Marketing Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
1 other identifier
observational
552
1 country
45
Brief Summary
This post-marketing surveillance (PMS) study for Sovaldi® tablets (sofosbuvir, SOF) administered in combination with Copegus® tablets (ribavirin, COPE) will evaluate the safety and efficacy of SOF administered in combination with ribavirin under real world use in Japan. Among adult patients with chronic genotype 2 hepatitis C virus (HCV) infection and treated with SOF+ribavirin in routine clinical use, the primary objective of this study is to evaluate the incidence of adverse drug reactions (ADRs) under real world settings.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2015
45 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 28, 2015
CompletedFirst Posted
Study publicly available on registry
September 1, 2015
CompletedStudy Start
First participant enrolled
September 15, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 5, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 5, 2017
CompletedJune 27, 2017
June 1, 2017
1.7 years
August 28, 2015
June 23, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of adverse drug reaction (ADR) under real world settings
Up to 16 weeks
Secondary Outcomes (2)
Proportion of participants with sustained virologic response (SVR) 12 and 24 weeks after discontinuation of therapy (SVR12 and SVR24)
Posttreatment Weeks 12 and 24
Proportion of participants with HCV NS5B resistance associated variants among patients who do not achieve SVR at 12 weeks
Approximately 12 weeks after treatment completion or discontinuation
Study Arms (1)
SOF+COPE
Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+COPE as part of routine clinical care at a participating clinical site.
Interventions
SOF 400 mg tablets administered orally once daily
COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
Eligibility Criteria
Adult patients with serogroup 2 (genotype 2) chronic HCV infection with or without compensated cirrhosis who take SOF+COPE as part of routine clinical care at a participating clinical site.
You may qualify if:
- Adult patients with serogroup 2 (genotype 2) chronic HCV infection with or without compensated cirrhosis
- Patients who are prescribed SOF+COPE
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Gilead Scienceslead
- Chugai Pharmaceuticalcollaborator
Study Sites (45)
Unknown Facility
Amagasaki-shi, Japan
Unknown Facility
Asahi-shi, Japan
Unknown Facility
Asahikawa-shi, Japan
Unknown Facility
Beppu-shi, Japan
Unknown Facility
Chichibu-shi, Japan
Unknown Facility
Fujioka-shi, Japan
Unknown Facility
Fukui-shi, Japan
Unknown Facility
Hamamatsu, Japan
Unknown Facility
Iizuka-shi, Japan
Unknown Facility
Inzai-shi, Japan
Unknown Facility
Ishinomaki-shi, Japan
Unknown Facility
Iwaki, Japan
Unknown Facility
Izunokuni-shi, Japan
Unknown Facility
Kahoku-gun, Japan
Unknown Facility
Kanazawa, Japan
Unknown Facility
Kirishima-shi, Japan
Unknown Facility
Kisarazu-shi, Japan
Unknown Facility
Kitamoto-shi, Japan
Unknown Facility
Kobe, Japan
Unknown Facility
Koshigaya-shi, Japan
Unknown Facility
Kure-shi, Japan
Unknown Facility
Moriguchi-shi, Japan
Unknown Facility
Nagakute-shi, Japan
Unknown Facility
Nagaoka-shi, Japan
Unknown Facility
Nagasaki, Japan
Unknown Facility
Nagoya, Japan
Unknown Facility
Nakagami-gun, Japan
Unknown Facility
Nanto-shi, Japan
Unknown Facility
Nishinomiya-shi, Japan
Unknown Facility
Ofukeshi, Japan
Unknown Facility
Okayama, Japan
Unknown Facility
Ome-shi, Japan
Unknown Facility
Osaka, Japan
Unknown Facility
Ōta-ku, Japan
Unknown Facility
Sapporo, Japan
Unknown Facility
Sasebo-Shi, Japan
Unknown Facility
Sendai, Japan
Unknown Facility
Shinagawa-ku, Japan
Unknown Facility
Shinjuku-ku, Japan
Unknown Facility
Tokorozawa-shi, Japan
Unknown Facility
Tokushima, Japan
Unknown Facility
Wakayama, Japan
Unknown Facility
Yachiyo-shi, Japan
Unknown Facility
Yokohama, Japan
Unknown Facility
Yufu-shi, Japan
Biospecimen
Whole blood
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Gilead Study Director
Gilead Sciences
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 28, 2015
First Posted
September 1, 2015
Study Start
September 15, 2015
Primary Completion
June 5, 2017
Study Completion
June 5, 2017
Last Updated
June 27, 2017
Record last verified: 2017-06